Kyntra Bio (KYNB) Leerink Global Healthcare Conference 2026 summary

Strategic transformation and financial highlights

• Completed sale of China operations to AstraZeneca for $220 million, enabling debt repayment and funding for new trials.

• Cash runway extended into 2028, supporting ongoing and future clinical development.

• Rebranded from FibroGen to Kyntra Bio, focusing on high-impact assets for patients and shareholders.

FG-3246 and FG-3180 prostate cancer program

• FG-3246 targets CD46, a novel epitope overexpressed in metastatic castration-resistant prostate cancer (mCRPC), showing promising efficacy and safety in early trials.

• FG-3180 PET imaging agent aids in patient selection, with strong correlation between CD46 uptake and treatment response.

• Phase II trial underway in pre-chemo mCRPC, with interim results expected in the second half of 2024 and final rPFS data anticipated by late 2027.

• Dose optimization and use of prophylactic G-CSF aim to improve efficacy and reduce adverse events.

• Potential for multiple registrational pathways, including monotherapy and combination approaches, in both all-comers and CD46-high populations.

Roxadustat for lower risk myelodysplastic syndrome (MDS)

• Roxadustat is phase III-ready for anemia in lower risk MDS, with orphan drug designation and a clarified regulatory path following FDA alignment.

• Prior phase III data showed meaningful benefit in high transfusion burden patients, supporting new trial design.

• New phase III trial will focus on patients requiring ≥4 RBC units in two consecutive eight-week periods, with efficacy endpoints of 8- and 16-week transfusion independence.

• Oral administration offers a differentiated option for elderly, fatigued patients, addressing a significant unmet need.

• MDS market projected to exceed $4 billion in five years, presenting a substantial commercial opportunity.